{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:46:48Z","timestamp":1787168808730,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jocn.2025.111712","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T04:21:04Z","timestamp":1761711664000},"page":"111712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Polypharmacy, Hyperpolypharmacy, and Associated Dementia: A Southeast Texas Nested Case-Control Study"],"prefix":"10.1016","volume":"143","author":[{"given":"Jacob","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Vasefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10248","key":"10.1016\/j.jocn.2025.111712_b0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the lancet commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jocn.2025.111712_b0010","first-page":"834","article-title":"Neuropathology of Dementia Disorders. CONTINUUM: Lifelong Learning","volume":"28","author":"Schneider","year":"2022","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jocn.2025.111712_b0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-27368-4","article-title":"Sex\/gender and socioeconomic differences in modifiable risk factors for dementia","volume":"13","author":"Geraets","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jocn.2025.111712_b0020","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neuroscience.2025.06.064","article-title":"Increased risk of Dementia and its Subtypes following Various Forms of acquired Brain Injury: a Meta-analysis and Systematic Review","volume":"580","author":"Thompson","year":"2025","journal-title":"Neuroscience"},{"key":"10.1016\/j.jocn.2025.111712_b0025","article-title":"Global status report on the public health response to dementia","author":"World Health Organization","year":"2021","journal-title":"World Health Organization"},{"issue":"1","key":"10.1016\/j.jocn.2025.111712_b0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.37022\/jiaps.v7i1.274","article-title":"Review on Alzheimer\u2019s disease: past, present and future","volume":"7","author":"Rayathala","year":"2022","journal-title":"Journal of Innovations in Applied Pharmaceutical Science (JIAPS)"},{"issue":"3","key":"10.1016\/j.jocn.2025.111712_b0035","first-page":"1","article-title":"Diagnosis of early Alzheimer\u2019s Disease: Clinical practice in 2021","volume":"8","author":"Porsteinsson","year":"2021","journal-title":"The Journal of Prevention of Alzheimer\u2019s Disease"},{"issue":"1","key":"10.1016\/j.jocn.2025.111712_b0040","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-021-01146-y","article-title":"Neuropathology of Alzheimer\u2019s Disease","volume":"19","author":"Trejo-Lopez","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"18","key":"10.1016\/j.jocn.2025.111712_b0045","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41582-022-00714-w","article-title":"Gene\u2013environment interactions in Alzheimer disease: the emerging role of epigenetics","volume":"18","author":"Migliore","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111712_b0050","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-022-02584-x","article-title":"Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases","volume":"19","author":"Boyd","year":"2022","journal-title":"J Neuroinflammation"},{"issue":"4","key":"10.1016\/j.jocn.2025.111712_b0055","article-title":"Alzheimer\u2019s Disease (AD): Environmental Modifiable Risk Factors","volume":"6","author":"Saragea","year":"2024","journal-title":"International Journal for Multidisciplinary Research"},{"issue":"2","key":"10.1016\/j.jocn.2025.111712_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000507078","article-title":"Neuropsychiatric Symptoms in Mild Cognitive Impairment: a Literature Review","volume":"49","author":"Martin","year":"2020","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"10.1016\/j.jocn.2025.111712_b0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ageing\/afaa228","article-title":"Mild Cognitive Impairment: the Manchester consensus","volume":"50","author":"Dunne","year":"2021","journal-title":"Age Ageing"},{"issue":"7","key":"10.1016\/j.jocn.2025.111712_b0070","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/alz.12291","article-title":"Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia","volume":"17","author":"McAleese","year":"2020","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"22","key":"10.1016\/j.jocn.2025.111712_b0075","doi-asserted-by":"crossref","first-page":"e2685","DOI":"10.1212\/WNL.0000000000012024","article-title":"Progression to Dementia in Mild Cognitive Impairment with Lewy Bodies or Alzheimer Disease","volume":"96","author":"Hamilton","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2025.111712_b0080","doi-asserted-by":"crossref","DOI":"10.1007\/s40520-020-01697-8","article-title":"Clinical and demographic parameters predict the progression from mild cognitive impairment to dementia in elderly patients","volume":"33","author":"Zuliani","year":"2021","journal-title":"Aging Clin Exp Res"},{"issue":"5","key":"10.1016\/j.jocn.2025.111712_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2019.10.001","article-title":"Polypharmacy: a general review of definitions, descriptions and determinants","volume":"75","author":"Guillot","year":"2020","journal-title":"Therapies"},{"issue":"3","key":"10.1016\/j.jocn.2025.111712_b0090","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s41999-021-00479-3","article-title":"Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences","volume":"12","author":"Pazan","year":"2021","journal-title":"European Geriatric Medicine"},{"issue":"11","key":"10.1016\/j.jocn.2025.111712_b0095","article-title":"An overview of prevalence, determinants and health outcomes of polypharmacy","volume":"11","author":"Khezrian","year":"2020","journal-title":"Ther Adv Drug Saf"},{"issue":"4","key":"10.1016\/j.jocn.2025.111712_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2022.01.012","article-title":"Older adults\u2019 willingness to consider deprescribing when experiencing hyperpolypharmacy","volume":"62","author":"Rana","year":"2022","journal-title":"J Am Pharm Assoc"},{"issue":"7","key":"10.1016\/j.jocn.2025.111712_b0105","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/14740338.2022.2044786","article-title":"Associations between hyper-polypharmacy and potentially inappropriate prescribing with clinical and functional outcomes in older adults","volume":"21","author":"Mekonnen","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jocn.2025.111712_b0110","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1382990","article-title":"The association between continuous polypharmacy and hospitalization, emergency department visits, and death in older adults: a nationwide large cohort study","volume":"15","author":"Chae","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111712_b0115","doi-asserted-by":"crossref","DOI":"10.1177\/00368504211070183","article-title":"Prevalence of polypharmacy and risk of potential drug-drug interactions among hospitalized patients with emphasis on the pharmacokinetics","volume":"105","author":"Georgiev","year":"2022","journal-title":"Sci Prog"},{"issue":"7","key":"10.1016\/j.jocn.2025.111712_b0120","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40262-024-01391-2","article-title":"Pharmacokinetics\u2013Pharmacodynamics Modeling for evaluating Drug\u2013Drug Interactions in Polypharmacy: Development and challenges","volume":"63","author":"Zhao","year":"2024","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.jocn.2025.111712_b0125","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2021.1195","article-title":"Prevalence of Central nervous System\u2013Active Polypharmacy among older adults with Dementia in the US","volume":"325","author":"Maust","year":"2021","journal-title":"J Am Med Assoc"},{"issue":"6","key":"10.1016\/j.jocn.2025.111712_b0130","first-page":"1037","article-title":"Anticholinergic\/Sedative Drug Burden and Subjective Cognitive Decline in older adults at risk of Alzheimer\u2019s Disease","volume":"76","author":"Margolis","year":"2021","journal-title":"The Journals of Gerontology: Series A"},{"issue":"1","key":"10.1016\/j.jocn.2025.111712_b0135","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/acps.13380","article-title":"The risk of dementia in patients using psychotropic drugs: Antidepressants, mood stabilizers or antipsychotics","volume":"145","author":"Tournier","year":"2022","journal-title":"Acta Psychiatr Scand"},{"issue":"9","key":"10.1016\/j.jocn.2025.111712_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamda.2023.06.035","article-title":"Long-Term Opioid Use and Dementia Risk in patients with Chronic Pain","volume":"24","author":"Sun","year":"2023","journal-title":"J Am Med Dir Assoc"},{"issue":"2","key":"10.1016\/j.jocn.2025.111712_b0265","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jamda.2019.05.010","article-title":"Association of Benzodiazepine and Anticholinergic Drug Usage with Incident Dementia: a prospective Cohort Study of Community-Dwelling older adults","volume":"21","author":"Hafdi","year":"2020","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"10.1016\/j.jocn.2025.111712_b0145","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-021-02695-9","article-title":"Persistent polypharmacy and fall injury risk: the Health, Aging and Body Composition Study","volume":"21","author":"Xue","year":"2021","journal-title":"BMC Geriatr"},{"issue":"9","key":"10.1016\/j.jocn.2025.111712_b0150","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/jech-2020-214238","article-title":"Medication adherence in community-dwelling older people exposed to chronic polypharmacy","volume":"75","author":"Franchi","year":"2021","journal-title":"J Epidemiol Community Health"},{"issue":"3","key":"10.1016\/j.jocn.2025.111712_b0155","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac058","article-title":"Longitudinal associations between falls and future risk of cognitive decline, the Motoric Cognitive Risk syndrome and dementia: the Einstein Ageing Study","volume":"51","author":"Jayakody","year":"2022","journal-title":"Age Ageing"},{"key":"10.1016\/j.jocn.2025.111712_b0160","first-page":"46","article-title":"Federal policy for the protection of human subjects","volume":"45 C.F.R. \u00a7","author":"U.S. Department of Health and Human Services","year":"2018","journal-title":"(\u2018Common Rule\u2019)"},{"key":"10.1016\/j.jocn.2025.111712_b0275","series-title":"Department of Health and Human Services","article-title":"Guidance on research involving coded private information or biological specimens","author":"U.s.","year":"2008"},{"issue":"9","key":"10.1016\/j.jocn.2025.111712_b0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-018-0114-5","article-title":"A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter","volume":"25","author":"Amato","year":"2018","journal-title":"Mol Psychiatry"},{"issue":"9","key":"10.1016\/j.jocn.2025.111712_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13607863.2021.1947967","article-title":"Centrally-acting anticholinergic drugs\u2013 associations with mortality, hospitalisation and cognitive decline following dementia diagnosis in people receiving antidepressant and antipsychotic drugs","volume":"26","author":"Bishara","year":"2022","journal-title":"Aging Ment Health"},{"issue":"344","key":"10.1016\/j.jocn.2025.111712_b0175","article-title":"Benzodiazepines and related drugs as a risk factor in Alzheimer\u2019s disease dementia","volume":"11","author":"Ettcheto","year":"2020","journal-title":"Front Aging Neurosci"},{"issue":"775144","key":"10.1016\/j.jocn.2025.111712_b0180","article-title":"Association between Z Drugs use and risk of Cognitive Impairment in Middle-Aged and older patients with Chronic Insomnia","volume":"15","author":"Guo","year":"2021","journal-title":"Front Hum Neurosci"},{"issue":"1133816","key":"10.1016\/j.jocn.2025.111712_b0185","article-title":"Anti-seizure medication exposure and the risk of dementia: a meta-analysis of observational studies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.jocn.2025.111712_b0190","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.gerinurse.2024.07.005","article-title":"Association between polypharmacy and cognitive impairment in older adults: a systematic review and meta-analysis","volume":"59","author":"Yu","year":"2024","journal-title":"Geriatr Nurs"},{"issue":"8","key":"10.1016\/j.jocn.2025.111712_b0270","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1080\/13607863.2018.1468411","article-title":"Association between polypharmacy and dementia \u2013 a systematic review and metaanalysis","volume":"23","author":"Leelakanok","year":"2018","journal-title":"Aging Ment Health"},{"key":"10.1016\/j.jocn.2025.111712_b0195","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.exger.2019.02.019","article-title":"The relationship between polypharmacy and trajectories of cognitive decline in people with dementia: a large representative cohort study","volume":"120","author":"Soysal","year":"2019","journal-title":"Exp Gerontol"},{"issue":"9","key":"10.1016\/j.jocn.2025.111712_b0200","doi-asserted-by":"crossref","DOI":"10.1111\/jgs.17291","article-title":"Polypharmacy among older adults with dementia compared with those without dementia in the United States","volume":"69","author":"Growdon","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.jocn.2025.111712_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0169463","article-title":"The Association between Polypharmacy and Dementia: a Nested Case-Control Study based on a 12-Year Longitudinal Cohort Database in South Korea","volume":"12","author":"Park","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jocn.2025.111712_b0210","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17m12043","article-title":"Association of Polypharmacy with Mild Cognitive Impairment and Cognitive Ability: a Nationwide Survey in Taiwan","volume":"79","author":"Cheng","year":"2018","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.jocn.2025.111712_b0215","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40520-019-01420-2","article-title":"Mild polypharmacy and MCI progression in older adults: the mediation effect of drug\u2013drug interactions","volume":"33","author":"Trevisan","year":"2019","journal-title":"Aging Clin Exp Res"},{"issue":"3","key":"10.1016\/j.jocn.2025.111712_b0220","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3233\/JAD-190284","article-title":"Potentially Inappropriate Medications and Polypharmacy: a Study of older people with Mild Cognitive Impairment and Mild Dementia","volume":"71","author":"Bonfiglio","year":"2019","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"6","key":"10.1016\/j.jocn.2025.111712_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jamda.2025.105586","article-title":"Polypharmacy and Mild Cognitive Impairment in older adults: a 3-year Study of DO-HEALTH","volume":"26","author":"de Godoi Rezende Costa Molino","year":"2025","journal-title":"J Am Med Dir Assoc"},{"issue":"3","key":"10.1016\/j.jocn.2025.111712_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.sapharm.2021.04.018","article-title":"The association between polypharmacy and cognitive ability in older adults: a national cohort study","volume":"18","author":"Aljeaidi","year":"2021","journal-title":"Res Soc Adm Pharm"},{"issue":"5","key":"10.1016\/j.jocn.2025.111712_b0235","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/pds.2116","article-title":"Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population","volume":"20","author":"Jyrkk\u00e4","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jocn.2025.111712_b0240","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.exger.2018.02.011","article-title":"Polypharmacy in people with dementia: Associations with adverse health outcomes","volume":"106","author":"Mueller","year":"2018","journal-title":"Exp Gerontol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111712_b0245","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-022-03346-3","article-title":"Predictors of falls and hospital admissions in people with cognitive impairment in day-care: role of multimorbidity, polypharmacy, and potentially inappropriate medication","volume":"22","author":"Scheel","year":"2022","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.jocn.2025.111712_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2021.104459","article-title":"Polypharmacy is associated with functional decline in Alzheimer\u2019s disease and Lewy body dementia","volume":"96","author":"Borda","year":"2021","journal-title":"Arch Gerontol Geriatr"},{"issue":"1","key":"10.1016\/j.jocn.2025.111712_b0255","doi-asserted-by":"crossref","DOI":"10.1177\/10998004241289942","article-title":"Impact of Polypharmacy on Symptoms and Health Outcomes in older adults with and without Alzheimer\u2019s Disease and Related Dementias","volume":"27","author":"Coates","year":"2024","journal-title":"Biol Res Nurs"},{"issue":"8","key":"10.1016\/j.jocn.2025.111712_b0260","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/1533317511432734","article-title":"Functional Decline Associated with Polypharmacy and Potentially Inappropriate Medications in Community-Dwelling older adults with Dementia","volume":"26","author":"Lau","year":"2011","journal-title":"American Journal of Alzheimer\u2019s Disease & Other Dementias"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758682500685X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096758682500685X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T23:17:41Z","timestamp":1769296661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096758682500685X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":55,"alternative-id":["S096758682500685X"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111712","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polypharmacy, Hyperpolypharmacy, and Associated Dementia: A Southeast Texas Nested Case-Control Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111712"}}